Caplin Point Laboratories vs Wockhardt: Share Price, PE and ROE Compared
- August 13, 2026
- Posted by: Kunal Singla
- Category: Market
Caplin Point MCap Rs 19,947 Cr, PE 30.70x, ROE 17.88%, zero debt. Wockhardt MCap Rs 30,984 Cr, PE 74.84x, ROE 5.75%.
Quick Answer
Caplin Point and Wockhardt are a contrasting pharma pair. Caplin at Rs 19,947 Cr runs a zero-debt operation with ROE 17.88% and trades at PE 30.70x. Wockhardt at Rs 30,984 Cr trades at a premium PE of 74.84x with ROE of only 5.75%, reflecting its novel antibiotic pipeline expectations. Caplin serves emerging markets; Wockhardt is focused on complex generics and novel molecules.
The Caplin Point Laboratories vs Wockhardt question comes up often among investors who follow the Pharmaceuticals space in India. Caplin Point MCap Rs 19,947 Cr, PE 30. 70x, ROE 17. This article goes through what each company does, their latest financial performance, and the key numbers that matter for anyone evaluating Caplin Point Laboratories vs Wockhardt as a research exercise.
All data cited here is sourced from publicly available company filings. Verify the latest prices and fundamentals on NSE or BSE before acting on any information.
Caplin Point Laboratories vs Wockhardt: Company Overview and Market Presence
Caplin Point Laboratories operates in the Pharmaceuticals segment and is listed on Indian exchanges. Caplin Point MCap Rs 19,947 Cr, PE 30 The company has built its market position over the years through its core offerings to customers across India.
Click Here – Get Free Investment Predictions
Wockhardt is the other side of this Caplin Point Laboratories vs Wockhardt comparison. 70x, ROE 17 It competes in the same Pharmaceuticals space, though its scale and strategy may differ significantly from Caplin Point Laboratories’s approach.
When investors look at the Caplin Point Laboratories vs Wockhardt pair, market capitalisation is usually the first filter. Caplin Point MCap Rs 19,947 Cr, PE 30. 70x, ROE 17. The size difference, if any, tells you something about liquidity and institutional ownership patterns.
Caplin Point Laboratories vs Wockhardt: Business Mix and Revenue Sources
To understand the Caplin Point Laboratories vs Wockhardt comparison fully, you need to look at how each company makes money. Caplin Point Laboratories’s revenue comes from its core Pharmaceuticals operations. Caplin Point Laboratories earns from the Pharmaceuticals segment.
Wockhardt similarly derives its earnings from the Pharmaceuticals space. Wockhardt operates in the Pharmaceuticals space. The product or service mix of the two companies can be similar or quite different depending on which subsegments each one serves.
Caplin Point Laboratories vs Wockhardt: Financial Results and Key Ratios
This is where the Caplin Point Laboratories vs Wockhardt comparison gets concrete. Return on equity, price-to-earnings ratio and market capitalisation are three metrics that help frame the relative position of each stock.
Caplin Point MCap Rs 19,947 Cr, PE 30 The profitability and efficiency ratios here reflect the latest available data from public filings.
70x, ROE 17 Both sets of numbers should be cross-checked against the latest quarterly reports from BSE or NSE before drawing any conclusions.
Compare Caplin Point Laboratories and Wockhardt on the Univest Screener
Caplin Point Laboratories vs Wockhardt: Valuation and What the Market Is Pricing In
Valuation is a core part of any Caplin Point Laboratories vs Wockhardt analysis. A high PE ratio can signal growth expectations or thin earnings. A low PE may indicate value or a business under stress. Neither is automatically good or bad without context.
Caplin Point MCap Rs 19,947 Cr, PE 30.70x, ROE 17.88%, zero debt. Wockhardt MCap Rs 30,984 Cr, PE 74.84x, ROE 5.75%. The Caplin Point Laboratories vs Wockhardt stock data above reflects figures sourced from publicly available data. Prices change daily, so treat this as a starting point for your own research rather than a definitive trading signal.
Dividend yield is another data point worth checking in the Caplin Point Laboratories vs Wockhardt pair. Some investors prioritise income alongside capital appreciation, and a consistent dividend track record can be a sign of earnings quality and management confidence in the cash flow.
Caplin Point Laboratories vs Wockhardt: Side-by-Side Comparison
The table below captures the most relevant metrics side by side for the Caplin Point Laboratories vs Wockhardt comparison.
| Parameter | Caplin Point Laboratories | Wockhardt |
|---|---|---|
| MCap | Rs 19,947 Cr | Rs 30,984 Cr |
| PE | 30.70x | 74.84x |
| ROE | 17.88% | 5.75% |
| Debt | Zero | 0.45 D/E |
What Should Investors Know About the Caplin Point Laboratories vs Wockhardt Choice
Every Caplin Point Laboratories vs Wockhardt research exercise should go beyond just looking at the current share price. The sector outlook for Pharmaceuticals companies, the trajectory of earnings growth, debt levels and management quality all feed into a complete picture.
For the Caplin Point Laboratories vs Wockhardt pair specifically: Caplin Point MCap Rs 19,947 Cr, PE 30. 70x, ROE 17. These numbers are a starting point. Investors should also look at the trend over four to eight quarters rather than just the latest standalone figure, since one strong quarter does not always reflect the underlying business quality.
If you are building a portfolio allocation decision around the Caplin Point Laboratories vs Wockhardt comparison, consider the risk profile of your overall portfolio first. Both companies operate in Pharmaceuticals, which carries its own sector-specific risks including regulatory changes, commodity cost pressure, competitive intensity and macroeconomic sensitivity.
Conclusion
The Caplin Point Laboratories vs Wockhardt comparison comes down to this: Caplin Point Laboratories and Wockhardt are both listed Indian companies in the Pharmaceuticals space, but they differ in scale, valuation, and financial profile. Caplin Point MCap Rs 19,947 Cr, PE 30. 70x, ROE 17.
Caplin Point MCap Rs 19,947 Cr, PE 30.70x, ROE 17.88%, zero debt. Wockhardt MCap Rs 30,984 Cr, PE 74.84x, ROE 5.75%. Before taking any position in either stock, verify the latest fundamentals on NSE or BSE and consult a SEBI-registered investment advisor (registration number INH000013776).
Download the Univest iOS App or Univest Android App to track Caplin Point Laboratories and Wockhardt live and get analyst-backed stock recommendations every day.
Disclaimer: Data and figures in this article are sourced from publicly available information and may not be fully accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice from Univest (SEBI RA INH000013776).
Frequently Asked Questions
What does Caplin Point Laboratories do?
Ans. Caplin Point Laboratories is a listed Indian company in the Pharmaceuticals segment. For the latest business updates, visit univest.in.
What does Wockhardt do?
Ans. Wockhardt is a listed Indian company in the Pharmaceuticals segment. For the latest business updates, visit univest.in.
Which is larger in the Caplin Point Laboratories vs Wockhardt comparison?
Ans. Based on current market cap data: Caplin Point MCap Rs 19,947 Cr, PE 30. Verify the latest figures on NSE or BSE.
How do PE ratios compare in Caplin Point Laboratories vs Wockhardt?
Ans. The PE ratio comparison is covered in the data table above. Verify current figures from NSE or BSE before investing.
What is the ROE of Caplin Point Laboratories?
Ans. The ROE of Caplin Point Laboratories is mentioned in the data table above. Verify from the latest quarterly filings.
Does Wockhardt pay dividends?
Ans. Dividend yield information for Wockhardt is included in the comparison above. Verify from NSE or BSE.
How should I evaluate Pharmaceuticals stocks?
Ans. For Pharmaceuticals stocks, review earnings quality, ROE trends, debt levels and sector outlook. Consult a SEBI-registered advisor (INH000013776) before investing.
